Global Adalimumab Market Size By Type (Adalimumab, Adalimumab Biosimilar), By Application (Adults, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Adalimumab Market was valued at USD 21.5 billion in 2023 and is projected to surpass USD 34.2 billion by 2031, growing at a CAGR of 6.1% during the forecast period from 2023 to 2031. Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), has gained significant traction for its efficacy in treating autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. The market is being driven by increasing autoimmune disease prevalence, a growing geriatric population, expanding biosimilar uptake, and continuous R&D advancements in biologics.

Drivers:

1. Rising Prevalence of Autoimmune Diseases:

A global increase in the incidence of chronic autoimmune disorders is significantly boosting the demand for Adalimumab. Conditions like rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease are on the rise, particularly in developed regions, driving the need for effective biologics.

2. Expanding Biosimilar Landscape:

The patent expiration of branded Adalimumab (e.g., Humira) has led to the entry of multiple biosimilars in various global markets. These lower-cost alternatives are enhancing accessibility and expanding market reach, particularly in cost-sensitive developing regions.

3. Technological Advancements and Formulation Innovations:

Improvements in drug delivery systems—such as subcutaneous auto-injectors—and innovations in formulation stability are enhancing patient compliance and safety, thus positively influencing the market.

Restraints:

1. High Treatment Costs and Limited Affordability:

Despite the rise of biosimilars, the overall treatment cost for biologics like Adalimumab remains high, especially in the absence of universal health coverage or insurance, limiting adoption in low-income markets.

2. Stringent Regulatory Approvals for Biosimilars:

Biosimilar developers face complex and time-consuming regulatory pathways across different jurisdictions, which can delay product launches and hinder market expansion.

Opportunity:

1. Penetration in Emerging Markets:

With healthcare infrastructure improving in Asia-Pacific, Latin America, and the Middle East, the adoption of biosimilar Adalimumab is poised to grow. These regions present significant untapped opportunities due to rising disease burden and growing access to biologics.

2. Increasing Indication Expansion through Clinical Trials:

Ongoing clinical research into the efficacy of Adalimumab for new indications such as hidradenitis suppurativa and non-infectious uveitis is likely to broaden the market scope and patient pool.

Market by System Type Insights:

Based on drug type, the Biosimilar Adalimumab segment is expected to exhibit the highest growth during the forecast period, fueled by cost-effectiveness and regulatory approvals in various global markets. However, the Branded Adalimumab segment continues to dominate in revenue due to strong physician trust and brand loyalty, particularly in North America and Europe.

Market by End-use Insights:

By end-use, the Hospital Pharmacies segment held the largest share in 2023, driven by institutional procurement practices and the need for specialist administration and monitoring. Meanwhile, Online Pharmacies are gaining momentum owing to rising e-commerce penetration and growing patient preference for convenient home delivery.

Market by Regional Insights:

In 2023, North America accounted for the largest market share due to robust healthcare infrastructure, high biologics uptake, and the dominance of branded Adalimumab. Europe follows closely with strong biosimilar adoption post-Humira patent expiry. The Asia-Pacific region is projected to witness the fastest growth due to increasing biosimilar availability, healthcare reforms, and rising patient awareness.

Competitive Scenario:

Key players in the Global Adalimumab Market include:

AbbVie Inc.

Amgen Inc.

Boehringer Ingelheim International GmbH

Pfizer Inc.

Samsung Bioepis

Sandoz (a Novartis Division)

Biocon Biologics

Coherus BioSciences

Fresenius Kabi

Mylan N.V. (Viatris)

These companies are leveraging strategies such as biosimilar development, strategic alliances, aggressive pricing, and expanding regional presence to capture greater market share.

Scope of Work – Global Adalimumab Market

Key Market Developments:

2023: Pfizer and Samsung Bioepis received FDA approval for their biosimilar Adalimumab formulation in the U.S., aiming to expand access through competitive pricing.

2024: AbbVie launched a high-concentration, citrate-free formulation of Humira, improving patient comfort and adherence.

2025: Sandoz announced expansion into Southeast Asia with its biosimilar Adalimumab portfolio, following regulatory clearances in multiple APAC countries.

FAQs:

1) What is the current market size of the Global Adalimumab Market?

The Global Adalimumab Market was valued at USD 21.5 billion in 2023.

2) What is the major growth driver of the Global Adalimumab Market?

The market is driven by the rising prevalence of autoimmune diseases and the growing adoption of cost-effective biosimilars.

3) Which is the largest region during the forecast period in the Global Adalimumab Market?

North America holds the largest market share due to advanced healthcare infrastructure and strong biologics uptake.

4) Which segment accounted for the largest market share in the Global Adalimumab Market?

The Hospital Pharmacies segment accounted for the largest share, supported by institutional procurement and specialist treatment needs.

5) Who are the key market players in the Global Adalimumab Market?

Key players include AbbVie, Amgen, Pfizer, Sandoz, Samsung Bioepis, Biocon Biologics, and Fresenius Kabi.